TGFB1 and renal fibrosis: It has been reported that in vivo ASIV can decrease renal mass loss, EMT, and the infiltration of inflammatory cells in UUO-induced renal fibrosis, and in vitro ASIV can significantly attenuate TGF-β1-induced fibrosis in human kidney-2 (HK-2) cells [33,34].